Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11642081 | 0.87 | HDAC1 (0.46) | GSK3BPTPN1CA1CA2CA9 | |
| SCHEMBL28782898 | 0.87 | CA1 (0.44) | GSK3BPTPN1GAAMAPTCA1 | |
| Hydrochloric Acid SCHEMBL5378576 | 0.81 | GSK3B (0.52) | GSK3BGAAMAPTCA1CA2 | |
| SCHEMBL1191123 | 0.80 | TTR (0.58) | GSK3BPTPN1 | |
| SCHEMBL6543881 | 0.78 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL5368082 | 0.78 | GSK3B (0.48) | GSK3BGAAMAPTCA1CA2 | |
| SCHEMBL2876065 | 0.77 | GSK3B (0.50) | GSK3BPTPN1GAACA1CA2 | |
| SCHEMBL20819692 | 0.77 | HDAC1 (0.52) | GSK3BPTPN1CA1CA2CA9 | |
| SCHEMBL5981761 | 0.77 | GSK3B (0.61) | GSK3BGAAMAPTCA1CA2 | |
| SCHEMBL7496254 | 0.76 | GSK3B (0.47) | GSK3BGAAMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912434-B | Synthesis method of phenylethanolamine beta receptor agonist | 上海安谱实验科技股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-109912434-A | The synthetic method of phenyl ethyl amine beta receptor agonist | 上海安谱实验科技股份有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-6747057-B2 | SUCH 1-(2-BROMO-4,5-DICHLORO-THIOPHEN-3-YL)-2-CHLORO-ETHANONE FOR TREATMENT OF ALZHEIMER'S DISEASE OR DIABETES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2004-06-08 | — | — | US | disclosed |
| US-20030199508-A1 | Compounds and their therapeutic use | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-23 | — | — | US | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199508-A1 | Compounds and their therapeutic use | CNKSR1, CBR1, CBR3 | GSK3B 4/4885PTPN1 1068/4885GAA 3411/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | GSK3B 3109/4885PTPN1 1274/4885GAA 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.